Neuronal Adenylyl Cyclase Targeting Central Plasticity for the Treatment of Chronic Pain

• Published in: Neurotherapeutics 2020-07, Vol.17 (3), p.861-873
• Main Authors: Li, Xu-Hui, Chen, Qi-Yu, Zhuo, Min
• Format: Article
• Language: English
• Subjects: Adenosine Triphosphate - administration & dosage; Adenosine Triphosphate - analogs & derivatives; Adenosine Triphosphate - metabolism; Adenylate cyclase; Adenylyl Cyclase Inhibitors - administration & dosage; Adenylyl Cyclase Inhibitors - metabolism; Adenylyl Cyclases - metabolism; Analgesics; Analgesics - administration & dosage; Analgesics - metabolism; Animal models; Animals; Biomedical and Life Sciences; Biomedicine; Chronic pain; Chronic Pain - drug therapy; Chronic Pain - metabolism; Drug Delivery Systems - methods; Excitability; Gabapentin; Humans; Long-term potentiation; Long-Term Potentiation - drug effects; Long-Term Potentiation - physiology; Narcotics; Neurobiology; Neurology; Neuronal Plasticity - drug effects; Neuronal Plasticity - physiology; Neurons - drug effects; Neurons - metabolism; Neurosciences; Neurosurgery; Opioids; Pain; Pain perception; Review; Synaptic plasticity
• ISSN: 1933-7213; 1878-7479; 1878-7479
• DOI: 10.1007/s13311-020-00927-1

Chronic pain is a major health problem and the effective treatment for chronic pain is still lacking. The recent crisis created by the overuse of opioids for pain treatment has clearly shown the need for non-addictive novel pain medicine. Conventional pain medicines usually inhibit peripheral nociceptive transmission and reduce central transmission, especially pain-related excitatory transmission. For example, both opioids and gabapentin produce analgesic effects by inhibiting the release of excitatory transmitters and reducing neuronal excitability. Here, we will review recent studies of central synaptic plasticity contributing to central sensitization in chronic pain. Neuronal selective adenylyl cyclase subtype 1 (AC1) is proposed to be a key intracellular protein that causes both presynaptic and postsynaptic forms of long-term potentiation (LTP). Inhibiting the activity of AC1 by selective inhibitor NB001 blocks behavioral sensitization and injury-related anxiety in animal models of chronic pain. We propose that inhibiting injury-related LTPs will provide new mechanisms for designing novel medicines for the treatment of chronic pain and its related emotional disorders.